Virtual Library

Start Your Search

Alessandro Leonetti



Author of

  • +

    P76 - Targeted Therapy - Clinically Focused - EGFR (ID 253)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P76.52 - Liquid Biopsy and PET Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC (ID 2978)

      00:00 - 00:00  |  Presenting Author(s): Alessandro Leonetti

      • Abstract
      • Slides

      Introduction

      Osimertinib resistance constitutes a major challenge for the management of advanced EGFR-mutated (adv-EGFR+) NSCLC and the identification of predictive factors is largely needed. We aimed to investigate a putative role of liquid biopsy (LB) and metabolic parameters in predicting response to osimertinib.

      Methods

      We prospectively enrolled adv-EGFR+ NSCLC patients (pts) who were treated with osimertinib both in first- (1L) and second-line (2L). Pts underwent LB before starting of osimertinib and EGFR activating mutation (EGFRact) allele frequency (AF) was assessed on circulating free DNA (cfDNA) by ddPCR. Pts with EGFRact AF > 0 were defined as shedders. FDG-PET was performed at baseline and after 1 month of treatment; metabolic response (MR) was assessed as per PERCIST 1.0 criteria. Tumor response was assessed by CT-scan after 2-3 months (mos) as per RECIST 1.1 criteria. FDG-PET parameters (maximum standardized uptake value [SUVmax], SUVpeak, lean body mass corrected SUV [SULpeak], total lesion glycolysis [TLG]) cut-offs were calculated using ROC curve analysis.

      Results

      23 pts with adv-EGFR+ NSCLC (1L=15; 2L=8) were enrolled at the time of data cut-off (April 21th, 2020). Overall, mPFS was 7.1 mos (95% CI, 0.3-13.9) and mOS was not reached (Range, 1.1-17.9). Basal shedders had a significantly shorter mPFS compared to non-shedders (mPFS: 3.6 vs 17.0 mos, p<0.05). Among all FDG-PET parameters, basal TLG (bTLG) was significantly related to basal EGFRact AF (Spearman r: 0.57, 95%CI 0.17-0.81, p<0.05). Pts who had a high bTLG had a significantly shorter mPFS vs pts with a low bTLG (mPFS: 3.6 vs 14.2 mos, p<0.05). Pts who had a high bTLG and were shedders had a significantly shorter mPFS vs pts who had only 1 of the 2 features and who had none (mPFS: 3.0 vs 7.1 vs 17.0 mos, respectively, p<0.05). Among basal shedders (n=11), the clearance of EGFRact after 1 month was significantly associated with MR (p<0.05). Pts who achieved a MR at the 1-month FDG-PET had a significantly longer mPFS vs pts who did not (mPFS: 14.2 vs 5.5 mos, p<0.05).

      Conclusion

      EGFRact shedding and high bTLG identified a poor responder group to osimertinib. Integration of basal and early cfDNA analysis and metabolic parameters might be a promising not-invasive approach to predict benefit to osimertinib.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.